Home > Insider Trading > Filing (0001179110-14-000628)

Filing Details

Accession Number:: 0001179110-14-000628
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2014-01-07 16:54:03
Reporting Period:: 2014-01-03

Filing Date:: 2014-01-07
Accepted Time:: 2014-01-07 16:54:03
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
792977	Amag Pharmaceuticals Inc.	AMAG	Pharmaceutical Preparations (2834)	042742593

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1537668	G Christopher White	1100 Winter Street Waltham MA 02451	Chief Business Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2014-01-06	2,500	$23.69	31,334	No	4	S	Direct
Common Stock	Disposition	2014-01-07	2,500	$24.10	28,834	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Direct

Footnotes

The shares reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person.
The shares sold on this date were sold in multiple transactions. The price reflected is the weighted average sales price per share of all shares sold under this reporting event on this date. The actual sales prices per share range from $23.30 - $23.95. Upon request by the Securities and Exchange Commission, AMAG Pharmaceuticals, Inc., or any security holder of the Issuer, the reporting person will provide full information regarding the number of shares sold at each price.
This total includes 5,000 shares delivered to the reporting person on January 3, 2014 pursuant to the partial vesting of a restricted stock unit award granted to the reporting person on January 3, 2012 and of which 2,500 shares were sold on January 6, 2014 as reported in this Form 4. This total also includes 834 unvested restricted stock units granted on February 24, 2010, 8,000 unvested restricted stock units granted pursuant to two separate grants on January 7, 2011, and 5,000 unvested restricted stock units granted on January 3, 2012, all of which were previously reported on Table II. Thus, after taking into account the delivery of shares on January 3, 2014, this total includes an aggregate of 18,834 unvested restricted stock units previously reported on Table II.
The shares sold on this date were sold in multiple transactions. The price reflected is the weighted average sales price per share of all shares sold under this reporting event on this date. The actual sales prices per share range from $23.84 - $24.82. Upon request by the Securities and Exchange Commission, AMAG Pharmaceuticals, Inc., or any security holder of the Issuer, the reporting person will provide full information regarding the number of shares sold at each price.